免疫性血小板缺血症患者的阿瓦特罗姆波帕格治疗反应:REAL-AVA 1.0研究
Abiola Oladapo1, Scott Kolodny2, Michael Vredenburg2
1Sobi Inc., 77 CityPoint, Fourth Avenue, Suite 300, Waltham, MA 02451, USA.
Therapeutic advances in hematology
|July 19, 2023
概括
在美国的一项真实研究中,阿瓦特罗姆波帕格 (AVA) 在免疫性血小板缺血症 (ITP) 患者中有效提高了血小板计数. 许多患者在没有救援药物的情况下达到有意义的血小板水平,并减少了其他ITP治疗.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 免疫性血小板缺血 (ITP) 是由于血小板数量低而导致的出血障碍.
- 血栓形成素受体激动剂 (TPO-RAs) 治疗ITP,最近的选择是AVA.
- 在ITP中对AVA有效性的真实数据有限.
研究的目的:
- 评估AVA在美国免疫血小板缺血症 (ITP) 患者的实际有效性.
- 描述患者的特征,治疗模式和ITP的AVA启动后的结果.
主要方法:
- 对行政索赔和实验室数据 (2017-2022) 的回顾性分析.
- 包括ITP和AVA处方的患者.
- 评估了临床意义的血小板计数 (≥30 × 109/l) 和同时使用药物的评估.
主要成果:
- 在有效性小组中的81%的患者实现了有意义的血小板计数.
- 大多数患者不需要救援药物 (类固醇:70%,免疫球蛋白:93%).
- 显著比例的患者停止了基线类固醇 (35%) 和免疫抑制剂 (57%).
结论:
- 阿瓦特罗姆波巴格 (AVA) 在提高ITP患者血小板计数方面表现出实际的有效性.
- 通过AVA治疗,可以减少对救援药物的需求,并停止其他疗法.
- 这些发现与临床试验数据一致,支持AVA在慢性ITP管理中的作用.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
216
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
216
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


